Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo

Yuanyuan Fu, Liang Hong, Jiecheng Xu, Guoping Zhong, Qiong Gu, Qianqian Gu, Yanping Guan, Xueping Zheng, Qi Dai, Xia Luo, Cui Liu, Zhiying Huang, Xiao-Ming Yin, Peiqing Liu, Min Li

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Human Atg4 homologs are cysteine proteases, which play key roles in the macroautophagy/autophagy process by cleaving Atg8 homologs for conjugation to lipid membranes and for deconjugation of Atg8 homologs from membranes. Expression of ATG4B is significantly increased in colorectal cancer cells compared to normal cells, suggesting that ATG4B may be important for cancer biology. Inhibition of ATG4B may reduce the autophagy activity, thereby sensitizing cancer cells to therapeutic agents. Thus, developing specific and potent ATG4B inhibitors for research as well as for potential therapeutic uses is highly needed. In this study, we integrated in silico screening and in vitro assays to discover a potent ATG4B inhibitor, named S130, from a noncommercial library. This chemical binds to ATG4B with strong affinity and specifically suppresses the activity of ATG4B but not other proteases. S130 did not cause the impairment of autophagosome fusion, nor did it result in the dysfunction of lysosomes. Instead, S130 might attenuate the delipidation of LC3-II on the autolysosomes to suppress the recycling of LC3-I, which normally occurs after LC3-II cleavage by ATG4B. Intriguingly, S130 induced cell death, which was accompanied with autophagy stress and could be further exacerbated by nutrient deprivation. Such cytotoxicity could be partially reversed by enhancing ATG4B activity. Finally, we found that S130 was distributed in tumor tissues in vivo and was also effective in arresting the growth of colorectal cancer cells. Thus, this study indicates that ATG4B is a potential anticancer target and S130 might be a novel small-molecule candidate for future cancer therapy.

Original languageEnglish (US)
JournalAutophagy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

welan
Autophagy
Colorectal Neoplasms
Cell Death
Neoplasms
Cysteine Proteases
Recycling
Therapeutic Uses
Membrane Lipids
Lysosomes
Computer Simulation
Libraries
In Vitro Techniques
Peptide Hydrolases
Food
Membranes

Keywords

  • Anti-tumor
  • ATG4B
  • autophagy
  • cell death
  • colorectal cancer
  • delipidation
  • FRET assay
  • xenografts

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. / Fu, Yuanyuan; Hong, Liang; Xu, Jiecheng; Zhong, Guoping; Gu, Qiong; Gu, Qianqian; Guan, Yanping; Zheng, Xueping; Dai, Qi; Luo, Xia; Liu, Cui; Huang, Zhiying; Yin, Xiao-Ming; Liu, Peiqing; Li, Min.

In: Autophagy, 01.01.2018.

Research output: Contribution to journalArticle

Fu, Yuanyuan ; Hong, Liang ; Xu, Jiecheng ; Zhong, Guoping ; Gu, Qiong ; Gu, Qianqian ; Guan, Yanping ; Zheng, Xueping ; Dai, Qi ; Luo, Xia ; Liu, Cui ; Huang, Zhiying ; Yin, Xiao-Ming ; Liu, Peiqing ; Li, Min. / Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. In: Autophagy. 2018.
@article{fe73f2071458443a97814c94a13af6cf,
title = "Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo",
abstract = "Human Atg4 homologs are cysteine proteases, which play key roles in the macroautophagy/autophagy process by cleaving Atg8 homologs for conjugation to lipid membranes and for deconjugation of Atg8 homologs from membranes. Expression of ATG4B is significantly increased in colorectal cancer cells compared to normal cells, suggesting that ATG4B may be important for cancer biology. Inhibition of ATG4B may reduce the autophagy activity, thereby sensitizing cancer cells to therapeutic agents. Thus, developing specific and potent ATG4B inhibitors for research as well as for potential therapeutic uses is highly needed. In this study, we integrated in silico screening and in vitro assays to discover a potent ATG4B inhibitor, named S130, from a noncommercial library. This chemical binds to ATG4B with strong affinity and specifically suppresses the activity of ATG4B but not other proteases. S130 did not cause the impairment of autophagosome fusion, nor did it result in the dysfunction of lysosomes. Instead, S130 might attenuate the delipidation of LC3-II on the autolysosomes to suppress the recycling of LC3-I, which normally occurs after LC3-II cleavage by ATG4B. Intriguingly, S130 induced cell death, which was accompanied with autophagy stress and could be further exacerbated by nutrient deprivation. Such cytotoxicity could be partially reversed by enhancing ATG4B activity. Finally, we found that S130 was distributed in tumor tissues in vivo and was also effective in arresting the growth of colorectal cancer cells. Thus, this study indicates that ATG4B is a potential anticancer target and S130 might be a novel small-molecule candidate for future cancer therapy.",
keywords = "Anti-tumor, ATG4B, autophagy, cell death, colorectal cancer, delipidation, FRET assay, xenografts",
author = "Yuanyuan Fu and Liang Hong and Jiecheng Xu and Guoping Zhong and Qiong Gu and Qianqian Gu and Yanping Guan and Xueping Zheng and Qi Dai and Xia Luo and Cui Liu and Zhiying Huang and Xiao-Ming Yin and Peiqing Liu and Min Li",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/15548627.2018.1517073",
language = "English (US)",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo

AU - Fu, Yuanyuan

AU - Hong, Liang

AU - Xu, Jiecheng

AU - Zhong, Guoping

AU - Gu, Qiong

AU - Gu, Qianqian

AU - Guan, Yanping

AU - Zheng, Xueping

AU - Dai, Qi

AU - Luo, Xia

AU - Liu, Cui

AU - Huang, Zhiying

AU - Yin, Xiao-Ming

AU - Liu, Peiqing

AU - Li, Min

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Human Atg4 homologs are cysteine proteases, which play key roles in the macroautophagy/autophagy process by cleaving Atg8 homologs for conjugation to lipid membranes and for deconjugation of Atg8 homologs from membranes. Expression of ATG4B is significantly increased in colorectal cancer cells compared to normal cells, suggesting that ATG4B may be important for cancer biology. Inhibition of ATG4B may reduce the autophagy activity, thereby sensitizing cancer cells to therapeutic agents. Thus, developing specific and potent ATG4B inhibitors for research as well as for potential therapeutic uses is highly needed. In this study, we integrated in silico screening and in vitro assays to discover a potent ATG4B inhibitor, named S130, from a noncommercial library. This chemical binds to ATG4B with strong affinity and specifically suppresses the activity of ATG4B but not other proteases. S130 did not cause the impairment of autophagosome fusion, nor did it result in the dysfunction of lysosomes. Instead, S130 might attenuate the delipidation of LC3-II on the autolysosomes to suppress the recycling of LC3-I, which normally occurs after LC3-II cleavage by ATG4B. Intriguingly, S130 induced cell death, which was accompanied with autophagy stress and could be further exacerbated by nutrient deprivation. Such cytotoxicity could be partially reversed by enhancing ATG4B activity. Finally, we found that S130 was distributed in tumor tissues in vivo and was also effective in arresting the growth of colorectal cancer cells. Thus, this study indicates that ATG4B is a potential anticancer target and S130 might be a novel small-molecule candidate for future cancer therapy.

AB - Human Atg4 homologs are cysteine proteases, which play key roles in the macroautophagy/autophagy process by cleaving Atg8 homologs for conjugation to lipid membranes and for deconjugation of Atg8 homologs from membranes. Expression of ATG4B is significantly increased in colorectal cancer cells compared to normal cells, suggesting that ATG4B may be important for cancer biology. Inhibition of ATG4B may reduce the autophagy activity, thereby sensitizing cancer cells to therapeutic agents. Thus, developing specific and potent ATG4B inhibitors for research as well as for potential therapeutic uses is highly needed. In this study, we integrated in silico screening and in vitro assays to discover a potent ATG4B inhibitor, named S130, from a noncommercial library. This chemical binds to ATG4B with strong affinity and specifically suppresses the activity of ATG4B but not other proteases. S130 did not cause the impairment of autophagosome fusion, nor did it result in the dysfunction of lysosomes. Instead, S130 might attenuate the delipidation of LC3-II on the autolysosomes to suppress the recycling of LC3-I, which normally occurs after LC3-II cleavage by ATG4B. Intriguingly, S130 induced cell death, which was accompanied with autophagy stress and could be further exacerbated by nutrient deprivation. Such cytotoxicity could be partially reversed by enhancing ATG4B activity. Finally, we found that S130 was distributed in tumor tissues in vivo and was also effective in arresting the growth of colorectal cancer cells. Thus, this study indicates that ATG4B is a potential anticancer target and S130 might be a novel small-molecule candidate for future cancer therapy.

KW - Anti-tumor

KW - ATG4B

KW - autophagy

KW - cell death

KW - colorectal cancer

KW - delipidation

KW - FRET assay

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=85053519970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053519970&partnerID=8YFLogxK

U2 - 10.1080/15548627.2018.1517073

DO - 10.1080/15548627.2018.1517073

M3 - Article

AN - SCOPUS:85053519970

JO - Autophagy

JF - Autophagy

SN - 1554-8627

ER -